Crosstalk from ErbB signaling pathway to Hippo signaling pathway
Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.
- Sentence from paper : Raf-1 prevents dimerization and phosphorylation of the activation loop of MST2 independently of its protein kinase activity.
Merlin in organ size control and tumorigenesis: Hippo versus EGFR?
- PubMed ID : 20713513
- Molecule in ErbB signaling pathway: RAF1
- Species : Cercopithecus aethiops
- Transcription : no
- Molecule in Hippo signaling pathway: STK4
- Tissue : COS-1 cell
- Regulation type : Activating
- Sentence from paper : In particular, Raf-1 has been shown to bind directly to Mst2 and prevent Mst2 from associating with RASSF1A, which, upon forming a complex with Mst2, stimulates its kinase activity and enhances its interaction with Lats1 (O'Neill et al. 2004; Matallanas et al. 2007).
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.
- Molecule in Hippo signaling pathway: YAP1
- Tissue : breast cancer cell line
- Regulation type : Activating
- Sentence from paper : We found that ERBB4 activated the transcriptional coactivator YAP, which promotes organ and tissue growth and is inhibited by the Hippo tumor-suppressor pathway.
The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.
- Molecule in Hippo signaling pathway: LATS1:MOB1A
- Tissue : cervical cancer cell line
- Regulation type : Inhibiting
- Sentence from paper : Treatment of ME180 cells with TGF-α resulted in a rapid increase in the phosphorylation of the EGFR and activation of the PI3K and MAPK signaling pathways.
|Molecule in ErbB signaling pathway||Molecule in Hippo signaling pathway||Tissue||Species||PubMed Identifier|
|RAF1||STK4||COS-1 cell||Cercopithecus aethiops||20713513|
|ERBB4||YAP1||breast cancer cell line||Homo sapiens||25492965|
|EGFR||LATS1:MOB1A||cervical cancer cell line||Homo sapiens||26417066|
Note: "Unknown" indicates that the molecule has not been identified.
Note: We direct each interaction from the molecule in the first pathway to the molecule in the second pathway. The direction of the interaction does not imply that the first molecule regulates the second molecule or that they directly interact. Hence, the interactions in this network may be indirect and may not indicate any mechanism.
XTalkDB does not contain any molecules mediating the crosstalk.
The name of the upstream (first) pathway in a pair of crosstalking pathways.
The name of the downstream (second) pathway in a pair of crosstalking pathways.
The string used as a structured query in PubMed that returned the recorded PMID as a result.
The PubMed identifier for the reported publication.
yes, if Pathway A elicits a downstream transcriptional response in Pathway B.
yes, if the crosstalk is transcriptional.
The downstream effect on Pathway B. This attribute can take one of the following two values:
The molecule in Pathway A responsible for mediating crosstalk to Pathway B.
|Molecule A Identifier|
Unique identifier for Molecule A in the namespace recorded in "Molecule A Source", e.g., the UniProt ID of a protein.
|Molecule A Source|
The name of database that the value in "Molecule A Identifier" comes from, e.g., "UniProt" if the molecule is a protein.
The molecule in Pathway B responsible for mediating crosstalk from Pathway A.
|Molecule B Identifier|
Unique identifier for Molecule B in the namespace recorded in "Molecule B Source", e.g., the UniProt ID of a protein.
|Molecule B Source|
The name of database that the value in "Molecule B Identifier" comes from, e.g., "UniProt" if the molecule is a protein.
The name of the species in which the crosstalk was observed.
The name of the tissue or cell line in which the crosstalk was observed.
The BRENDA Tissue Ontology (BTO) Identifier of the tissue or cell line in which the crosstalk was observed.
Notes on the experimental condition in the publication.
|Sentence from paper|
The sentence in the publication supporting the crosstalk. We record a sentence only if it states that Pathway A increases or decreases Pathway B signaling. The sentence may also include information about the proteins or genes responsible for mediating the crosstalk.
|Misleading evidence for crosstalk|
A sentence in the paper that appears to support evidence for crosstalk when the study does not conclude there is crosstalk.
A curator's notes that may provide rationale for the values recorded for the attributes.
*This attribute may represent either an individual molecule or several molecules. We use the following syntax for this attribute.
- colon (:): The molecules participate in the complex, e.g., SMAD3:SMAD4 in the case of crosstalk from the TGF-beta signaling pathway to the Hippo signaling pathway (the complex consisting of SMAD3 and SMAD4 mediates this crosstalk).
- slash (/): Either of the molecules can mediate the crosstalk, e.g., YAP1/WWTR1 for the same pair of pathways (YAP1 or WWTR1 can mediate the crosstalk).
- comma (,): All the molecules are required for the crosstalk but they do not form a complex, e.g., TSC2,RPTOR for the crosstalk from the MAPK signaling pathway to the mTOR signaling pathway (both TSC2 and RPTOR act as mediators).
- brackets (): If we cannot identify the specific molecule, we record all molecules in the family, e.g., [TEAD1/TEAD2/TEAD3/TEAD4]. In this case, the publication only listed the protein TEAD as mediating the crosstalk (from the Hippo signaling pathway to the Wnt signaling pathway).